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Introduction
Realization about the adverse effects of radiation began imme-diately after the discovery of X-ray in the form of skin cancer. Simultaneously, the awareness about existence of radionucleides 
intensified the threat of radiation. Rapid advancement in technology also 
further added varied kinds of radiation stresses [1-3].
Radiation damage is to a large extent caused by overproduction of re-
active oxygen species (ROS) which cause disruption of membrane lipids 
leading to subsequent formation of peroxide radicals. Moreover, certain 
cells have higher levels of reactive oxygen species (ROS) than normal 
cells, and ROS are, in turn, responsible for the maintenance of cancer 
phenotype. There is an equilibrium between a free radical (FR)/reactive 
oxygen species (ROS) formation and endogenous antioxidant defense 
mechanisms, but if this balance is disturbed, it can produce oxidative 
stress. Oxidative stress, which is the imbalance between oxidant and 
antioxidants in favor of the oxidants, can result in injury to all important 
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Radiation damage is to a large extent caused by overproduction of reactive oxygen 
species (ROS). Radioprotectors are agents or substances that reduce the effects of ra-
diation in healthy normal tissues while maintaining the sensitivity to radiation damage 
in tumor cells.
Radioprotectors are agents or substances that reduce the effects of radiation in healthy 
normal tissues while maintaining the sensitivity to radiation damage in tumor cells
Cimetidine was found more effective when used in vivo; this effect might be due to 
the augmentation of the presence of Sulphur atom in the compound which is ‎important 
for their scavenging activity.
Recently, a new herbal-based medicine with immunomodulatory capacities, Setarud 
(IMOD), was introduced as an additional therapy in various inflammatory diseases 
and HIV infection.   
IMOD is a mixture of herbal extracts enriched with selenium. Selenium confers pro-
tection by inducing or activating cellular free-radical scavenging systems and by en-
hancing peroxide breakdown. This article suggests that nontoxic amount of IMOD 
and cimetidine have radioprotective properties and could reduce cytotoxic effects of 
radiation.
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cellular components like proteins, DNA and 
membrane lipids causing cell death [3-6]. 
Although radiation therapy remains one of 
the most effective modalities for neoplastic 
disease, the damage caused by ionizing radia-
tion (IR) in the small intestine and bone mar-
row remains a concern. A major goal of radia-
tion oncology is the radioprotection of normal 
tissues to improve the therapeutic index. In 
addition, nuclear accidents lead to risk of ra-
diation exposure, which can cause radiation-
induced injury; therefore, effective therapeutic 
remedies are urgently needed, and identifying 
effective and useful substances for the preven-
tion or treatment of intestinal and bone mar-
row injury due to radiation exposure are criti-
cal [7-10].
Radioprotectors are agents or substances that 
reduce the effects of radiation in healthy nor-
mal tissues while maintaining the sensitivity 
to radiation damage in tumor cells. They have 
the potential to protect non-tumor tissues from 
the cytotoxic effects of the ionizing radiation, 
with a relevant impact on the therapeutic in-
dex of the radiotherapy treatment [11-13].
Waller Reed Army Research Institute syn-
thesized and tested over 4,000 compounds and 
found the most effective compound to be WR-
2721 (Amifostine) [14]. It is currently being 
used in cancer patients to reduce the side ef-
fects of radio- and chemotherapy. It is limited 
in use due to its cumulative toxicity in daily 
administration with radiotherapy, which is 
manifested as nausea, vomiting, hypotension, 
allergic reactions, etc. [15-17].
Thus, there is still an urgent need to iden-
tify novel, nontoxic, effective and convenient 
compounds to protect humans [18, 19].
Due to water radiolysis, the most abundant 
intracellular compounds and various types of 
free radicals are generated such as hydroxyl 
radicals (OH˚), hydrogen radicals (H˚) and 
solvated electrons [e - (aq)]. In the presence 
of oxygen, reactive oxygen species (ROS) 
such as superoxide anion (O2 ) and hydrogen 
peroxide (H2O2 ) are also formed leading to 
induction of more DNA damage and radiation 
cytotoxicity in cells [20-22]. OH˚ is generally 
considered the most damaging of the oxygen-
based free radicals and it is believed to account 
for an estimated 50% of the total damages in-
duced by free radical mechanisms [21, 23]. 
Cimetidine, an antagonist of histamine type 
II receptors, usually used for peptic ulcer treat-
ment, has been shown to play a role in immune 
system by anti-suppressor cell activity [24] 
and also when used with radiation effectively 
helped recovery of lymphohematopoetic sys-
tem. At cellular level, it was effective against 
the clastogenic effects of gamma rays and low 
doses of neutrons [24, 25].
Cimetidine, a selective histamine-2 receptor 
antagonist, has attracted interest because of its 
potential as an immune response-modifying 
drug. Most data suggest that cimetidine has 
a stimulatory action on the immune system, 
possibly by blocking receptors on subsets of 
T-lymphocytes and inhibiting histamine-in-
duced immune suppression. Several studies 
have shown that cimetidine can affect a rela-
tive number of CD8 + ve lymphocytes and 
increase the NK cell activity as well as the 
antibody-dependent cellular cytotoxicity. Ci-
metidine has also been used successfully to 
restore immune functions in patients with ma-
lignant disorders, hypogammaglobulinemia 
and AIDS-related complexes [26, 27].
The mechanism by which cimetidine reduc-
es clastogenic effects of radiation is not well 
understood. We propose that it might act by 
a radical scavenging mechanism via enzyme 
catalysis [28, 31].
They can scavenge OH° with rate constant 
1.6×1010 mol-1 s -1 and 7.5×109 mol-1 s 
-1 for cimetidine and ranitidine, respectively 
[32].
Recently, a new herbal-based medicine 
with immunomodulatory capacities, Setarud 
(IMOD), is introduced as an additional thera-
py in various inflammatory diseases and HIV 
infection.  IMOD Treatment Skews T Helper 
Cell Polarization Toward Promotes TH2IL-
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12p70 expression is necessary for TH1 differ-
entiation, as   inhibition of IL-12p70 skews T 
cells responses toward TH2 cytokines profile 
[33, 34]. Because IMOD inhibits the produc-
tion of pro-inflammatory cytokines includ-
ing IL-12p70, investigated whether IMOD 
modulated T helper cell polarization. DCs 
were stimulated with different concentrations 
of IMOD in the presence or   absence of LPS 
[34, 35]. Subsequently, DCs were washed and 
mixed with Naïve CD4+ T cells and T cell 
polarization was investigated. Results show 
that IMOD-stimulated DCs skewed T cells 
responses is further supported by the attenua-
tion of T cell activation by IMOD-treated DC. 
Thus, IMOD strongly counteracts with pro-
inflammatory responses which might prevent 
immune-mediated tissue damage [34, 36].
IL-12p70 expression is necessary for TH1 
differentiation, as inhibition of IL-12p70 
skews T cells responses toward TH2 cytokines 
profile. Because IMOD inhibits the production 
of pro-inflammatory cytokines including IL-
12p70, investigated whether IMOD modulat-
ed T helper cell polarization. DCs were stimu-
lated with different concentrations of IMOD in 
the presence or absence of LPS. Subsequently, 
DCs were washed and mixed with naïve CD4+ 
T cells and T cell polarization was investigat-
ed. Results show that IMOD stimulated DCs 
skewed T cells responses were further sup-
ported by the attenuation of T cell activation 
by IMOD-treated DC. Thus, IMOD strongly 
counteracts with pro-inflammatory responses 
which might prevent immune-mediated tissue 
damage [37, 38].
This drug is used for the treatment of human 
immunodeficiency virus (HIV) infection by 
increasing CD4 lymphocytes [39].
These cells are measured in the blood as 
CD4 and CD8 counts [39]. The CD4 count is 
a reflection of immune system efficiency; the 
lower the CD4 count, the weaker the immune 
system will be [37].
IMOD has been shown to affect immune re-
sponses in animal studies IMOD consisting of 
a mixture of herbal extracts (Tanacetum vul-
gare, Rosacanina and Urticadioica) supple-
mented with selenium. Different herbal ingre-
dients of IMOD possess anti-inflammatory, 
anti-viral and immune -modulating properties; 
the lectin and polysaccharide fractions of U. 
dioica (nettle) exhibit anti-viral and anti-in-
flammatory properties [34-36].
Selenium is an essential trace element that 
plays a key role in protecting cells from oxi-
dative stress, and selenium supplementation in 
the diet may reduce the risk of cardiomyopa-
thy, cancer and immune disorders in humans 
[34, 40, 41].
Discussion
Ionizing radiation causes harmful effects 
through the generation of free radicals. When 
water, the most abundant intra- and extracel-
lular material, is exposed to ionizing radiation, 
decomposition occurs through which a variety 
of ROSs such as the superoxide radical, hydro-
gen peroxide (H2O2) and the hydroxyl radi-
cal (OH–) are generated. These ROSs formed 
in cells contribute to radiation injury in cells. 
Although all respiring cells are equipped with 
protective enzymes such as SOD and CAT or 
GPX, increased oxidative stress in cells that 
stem from ionizing radiation may overwhelm 
the protective systems, leading to cell injury 
[42-40]. SOD converts superoxide anion 
radical to H2O2, thus decreasing the amount 
of and the formation of peroxynitrite anion 
(ONOO–), a highly destructive product of the 
interaction between O2 and nitric oxide [42].
Radiation chemical studies have shown that 
free radicals are primarily responsible for 
the indirect effects of radiation. These drugs, 
when applied in vivo, also showed radiopro-
tective effects on mouse bone marrow eryth-
rocytes [24, 45].
Cimetidine was found more effective when 
used in vivo (Mozdarani and Gharbali 1993) 
[28]. This effect might be due to the augmen-
tation of the presence of Sulphur atom in the 
compound which is important for their scav-
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enging activity [46].
A study by S. Kabodanian Ardestani 
con¬firmed that cimetidine and ranitidine 
could control these changes; therefore, they 
can be used as radioprotective drugs [32]. 
H2-receptor antagonists are scavengers of hy-
droxyl radicals with a very high rate constant 
[47, 48].
H2-receptor antagonists effectively reduce 
the clastogenic effects of radiation with a dose 
reduction factor (DRF) of 1.5-2 in human 
lymphocytes in vitro. The way in which these 
drugs reduce the clastogenic effects of radia-
tion might be via radical scavenging mecha-
nism [46, 49].
IMOD is a mixture of herbal extracts en-
riched with selenium [38, 50]. Selenium con-
fers protection by inducing or activating cel-
lular free-radical scavenging systems and by 
enhancing peroxide breakdown [51, 52].
Selenium is an essential constituent of glu-
tathione peroxidase. This enzyme destroys hy-
drogen peroxide and organic hydroperoxides 
by using reducing equivalents from glutathi-
one [53]. Nontoxic levels of Na2SeO3 (sele-
nium) significantly inhibit cellular transforma-
tion by x-rays, benzo[a]pyrene and tryptophan 
pyrolysate; studies show that when selenium 
is added to C3H/1OT-1/2 cells as Na2SeO3 at 
concentrations of 2.5 tiM, it inhibits transfor-
mation induced by x-rays and by two chemical 
carcinogens, benzo[a]pyrene, an environmen-
tal pollutant and tryptophan pyrolysate (Trp-
P-2), a pyrolysis product from broiled protein 
foods [54, 55].
 All three oncogenic agents are producers of 
free oxygen species for selenium inhibits radi-
ation-induced agents [56].
Mutlu-Türkoglu et al. demonstrated a pro-
tective effect of selenium and vitamin E on 
rat intestine that correlated with an increase 
of intestinal GPX activity [57]. These results 
seem to indicate a radioprotective effect of se-
lenium on normal tissues. Hehr et al. showed 
a radioprotective effect of selenium in normal 
tissues (fibroblasts) but not in tumor cells [58]. 
Schleicher et al. found a stronger radioprotec-
tive effect in human endothelial cell lines than 
in cervix squamous carcinoma cells [58-60].
Biologically active compounds of Laminaria 
digitata Khorbi, particularly oligoglucan Lam-
inarin (a linear beta-1,3 glucan) were identi-
fied as immune-modulator enhancing mono-
cyte-macrophage activity [61].
Homeostasis among leukocytes was ob-
tained in short periods (3 weeks). According 
to the results revealed in this study, nutraceu-
ticals with such radioprotective properties are 
strongly recommended in radiation
protection, particularly because some inter-
ventional procedures with long screening pe-
riods and multiple image acquisition may give 
rise to deterministic effects in both staff and 
patients [62-64].
Ching et al. (1993) demonstrated that hista-
mine H2-receptor antagonists such as cimeti-
dine, ranitidine and famotidine are, in addition 
to being good inhibitors of histamine-stimu-
lated gastric acid secretion, highly powerful 
hydroxyl-radical scavengers [30, 65, 66]. 
H2-receptor antagonists such as cimetidine 
could inhibit hemopoietic reconstruction in re-
generating bone marrow after sublethal gam-
ma ray irradiation. Therefore, it is probable 
that cimetidine is unable to help bone marrow 
cell reconstruction after gamma irradiation 
[24, 30, 65].
Because of radioprotective effects of cimeti-
din and IMODE, the use of both drugs can 
cause more effective protection of cells from 
adverse effects of ionization radiation.
Conclusion
Radioprotectors protect against the deleteri-
ous effects of ionizing mainly by scavenging 
by-products from the biological environment. 
Oxidative molecules or ion¬izing radiation 
may be an effective approach in diminishing 
undesirable effects of radia¬tion byproducts. 
This article suggests that nontoxic amount of 
IMOD and cimetidine demonstrate radiopro-
tective properties which could reduce cytotox-
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ic effects of radiation.
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